규제 업데이트
2026년 9월 25일•1분 읽기
FDA Approves Ranbaxy Gabapentin Tablet ANDA076605 (600 mg & 800 mg)
The FDA approved application ANDA076605 for Ranbaxy’s oral gabapentin tablets (600 mg and 800 mg). Both products are currently listed as discontinued.
규제 업데이트
2026년 9월 16일•1분 읽기
FDA Approves ANDA090007 for Generic Gabapentin Capsules
FDA has approved ANDA090007 for generic gabapentin oral capsules in 100 mg, 300 mg, and 400 mg strengths, manufactured by Time Cap Laboratories, Bi‑Coastal Pharma, and Marksans Pharma.
규제 업데이트
2026년 9월 9일•1분 읽기
FDA Approves ANDA 076672 for Oral Gabapentin Solution (250 mg/5 ml) by TARO
The FDA granted approval (AP) for ANDA 076672, an oral gabapentin solution 250 mg/5 ml submitted by TARO. The product is listed as discontinued.
규제 업데이트
2026년 8월 24일•1분 읽기
FDA Approves ANDA076877 for Gabapentin Tablets (Discontinued)
FDA approved ANDA076877 for gabapentin 600mg and 800mg oral tablets submitted by Senores Pharms; both products are listed as discontinued.
규제 업데이트
2026년 8월 24일•1분 읽기
MHRA Reviews Addiction Warnings for Gabapentinoids, Benzodiazepines and Z‑Drugs
The UK Medicines and Healthcare products Regulatory Agency has re‑examined safety warnings on gabapentin, pregabalin, benzodiazepines and Z‑drugs, with findings published in a Public Assessment Report.
2